within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FF03_Durvalumab;

model Durvalumab
  extends Pharmacolibrary.Drugs.ATC.L.L01FF03;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01FF03</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Durvalumab is a human monoclonal antibody that blocks programmed death-ligand 1 (PD-L1), thereby enhancing T-cell-mediated immune response against tumor cells. It is primarily used for the treatment of locally advanced or metastatic urothelial carcinoma and non-small cell lung cancer, and is approved for clinical use.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult cancer patients (including non-small cell lung cancer, urothelial carcinoma). Parameters reported for intravenous administration in adults.</p><h4>References</h4><ol><li><p>Davar, D, et al., &amp; Zamarin, D (2024). Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV-GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors. <i>Journal for immunotherapy of cancer</i> 12(11) –. DOI:<a href=\"https://doi.org/10.1136/jitc-2024-009336\">10.1136/jitc-2024-009336</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39551600/\">https://pubmed.ncbi.nlm.nih.gov/39551600</a></p></li><li><p>O&#x27;Hara, MH, et al., &amp; Wang-Gillam, A (2020). Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors. <i>Journal of pancreatic cancer</i> 6(1) 21–31. DOI:<a href=\"https://doi.org/10.1089/pancan.2019.0018\">10.1089/pancan.2019.0018</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32219196/\">https://pubmed.ncbi.nlm.nih.gov/32219196</a></p></li><li><p>Patel, MR, et al., &amp; Hamilton, EP (2025). Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid Tumors. <i>Targeted oncology</i> 20(1) 127–138. DOI:<a href=\"https://doi.org/10.1007/s11523-024-01110-8\">10.1007/s11523-024-01110-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39560862/\">https://pubmed.ncbi.nlm.nih.gov/39560862</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Durvalumab;
